Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis

  • An Erratum to this article was published on 07 November 2011


Rapidly progressive glomerulonephritis (RPGN) is a life-threatening clinical syndrome and a morphological manifestation of severe glomerular injury that is marked by a proliferative histological pattern ('crescents') with accumulation of T cells and macrophages and proliferation of intrinsic glomerular cells. We show de novo induction of heparin-binding epidermal growth factor–like growth factor (HB-EGF) in intrinsic glomerular epithelial cells (podocytes) from both mice and humans with RPGN. HB-EGF induction increases phosphorylation of the epidermal growth factor receptor (EGFR, also known as ErbB1) in mice with RPGN. In HB-EGF–deficient mice, EGFR activation in glomeruli is absent and the course of RPGN is improved. Autocrine HB-EGF induces a phenotypic switch in podocytes in vitro. Conditional deletion of the Egfr gene from podocytes of mice alleviates the severity of RPGN. Likewise, pharmacological blockade of EGFR also improves the course of RPGN, even when started 4 d after the induction of experimental RPGN. This suggests that targeting the HB-EGF–EGFR pathway could also be beneficial in treatment of human RPGN.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Induction of renal HB-EGF synthesis leads to glomerular activation of EGFR during RPGN.
Figure 2: HB-EGF induces a migratory phenotype in podocytes in vitro.
Figure 3: Deletion of Hbegf gene prevents fatal renal destruction.
Figure 4: Selective deletion of Egfr from podocytes protects from RPGN.
Figure 5: Delayed EGFR tyrosine kinase inhibition stops development of crescentic RPGN.
Figure 6: HB-EGF expression is induced in human crescentic glomerulonephritis.

Change history

  • 07 November 2011

     In the version of this article initially published, the affiliations of the author Nathalie Sabaa were misidentified as affiliations 3 and 4. Her correct affiliations are 6 and 7. The error has been corrected in the HTML and PDF versions of the article.


  1. 1

    Jennette, J.C. & Thomas, D.B. Crescentic glomerulonephritis. Nephrol. Dial. Transplant. 16 (suppl. 6), 80–82 (2001).

  2. 2

    Feng, L. et al. Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats. J. Clin. Invest. 105, 341–350 (2000).

  3. 3

    Yoshizumi, M. et al. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J. Biol. Chem. 267, 9467–9469 (1992).

  4. 4

    Kume, N. & Gimbrone, M.A. Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 93, 907–911 (1994).

  5. 5

    Marikovsky, M. et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc. Natl. Acad. Sci. USA 90, 3889–3893 (1993).

  6. 6

    Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C. & Klagsbrun, M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251, 936–939 (1991).

  7. 7

    Blotnick, S., Peoples, G.E., Freeman, M.R., Eberlein, T.J. & Klagsbrun, M. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA 91, 2890–2894 (1994).

  8. 8

    Neale, T.J., Tipping, P.G., Carson, S.D. & Holdsworth, S.R. Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet 2, 421–424 (1988).

  9. 9

    Tipping, P.G. & Holdsworth, S.R. T cells in glomerulonephritis. Springer Semin. Immunopathol. 24, 377–393 (2003).

  10. 10

    Segerer, S. et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J. Am. Soc. Nephrol. 11, 2231–2242 (2000).

  11. 11

    Lloyd, C.M. et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185, 1371–1380 (1997).

  12. 12

    Besse-Eschmann, V., Le Hir, M., Endlich, N. & Endlich, K. Alteration of podocytes in a murine model of crescentic glomerulonephritis. Histochem. Cell Biol. 122, 139–149 (2004).

  13. 13

    Moeller, M.J. et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J. Am. Soc. Nephrol. 15, 61–67 (2004).

  14. 14

    Le Hir, M. et al. Podocyte bridges between the tuft and Bowman's capsule: an early event in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 12, 2060–2071 (2001).

  15. 15

    Thorner, P.S., Ho, M., Eremina, V., Sado, Y. & Quaggin, S. Podocytes contribute to the formation of glomerular crescents. J. Am. Soc. Nephrol. 19, 495–502 (2008).

  16. 16

    Bariéty, J. & Bruneval, P. Activated parietal epithelial cells or dedifferentiated podocytes in FSGS: can we make the difference? Kidney Int. 69, 194 (2006).

  17. 17

    Schiwek, D. et al. Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. Kidney Int. 66, 91–101 (2004).

  18. 18

    Simpson, K.J. et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat. Cell Biol. 10, 1027–1038 (2008).

  19. 19

    Hancock, W.W. & Atkins, R.C. Cellular composition of crescents in human rapidly progressive glomerulonephritis identified using monoclonal antibodies. Am. J. Nephrol. 4, 177–181 (1984).

  20. 20

    Lin, F. et al. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J. Immunol. 172, 2636–2642 (2004).

  21. 21

    Peoples, G.E. et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc. Natl. Acad. Sci. USA 92, 6547–6551 (1995).

  22. 22

    Lee, D. et al. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol. Cell. Biol. 24, 8907–8916 (2004).

  23. 23

    Osherov, N. & Levitzki, A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 225, 1047–1053 (1994).

  24. 24

    Faul, C., Asanuma, K., Yanagida-Asanuma, E., Kim, K. & Mundel, P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17, 428–437 (2007).

  25. 25

    Lee, Y.J., Shin, S.J., Lin, S.R., Tan, M.S. & Tsai, J.H. Increased expression of heparin binding epidermal growth-factor-like growth factor mRNA in the kidney of streptozotocin-induced diabetic rats. Biochem. Biophys. Res. Commun. 207, 216–222 (1995).

  26. 26

    Paizis, K. et al. Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. Kidney Int. 53, 1162–1171 (1998).

  27. 27

    Khong, T.F. et al. Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis. Kidney Int. 58, 1098–1107 (2000).

  28. 28

    Levy, J.B., Turner, A.N., Rees, A.J. & Pusey, C.D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 134, 1033–1042 (2001).

  29. 29

    Salama, A.D., Levy, J.B., Lightstone, L. & Pusey, C.D. Goodpasture's disease. Lancet 358, 917–920 (2001).

  30. 30

    Topham, P.S. et al. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J. Clin. Invest. 104, 1549–1557 (1999).

  31. 31

    Ng, Y.Y. et al. Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol. Dial. Transplant. 14, 2860–2872 (1999).

  32. 32

    Nikolic-Paterson, D.J. & Atkins, R.C. The role of macrophages in glomerulonephritis. Nephrol. Dial. Transplant. 16 (suppl. 5), 3–7 (2001).

  33. 33

    Boucher, A., Droz, D., Adafer, E. & Noel, L.H. Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. Lab. Invest. 56, 526–533 (1987).

  34. 34

    Kalluri, R., Danoff, T.M., Okada, H. & Neilson, E.G. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J. Clin. Invest. 100, 2263–2275 (1997).

  35. 35

    Guettier, C. et al. Immunohistochemical demonstration of parietal epithelial cells and macrophages in human proliferative extra-capillary lesions. Virchows Arch. A Pathol. Anat. Histopathol. 409, 739–748 (1986).

  36. 36

    Levy, J.B. & Pusey, C.D. Anti-glomerular basement membrane disease. in Oxford Textbook of Medicine, 4th edn. (eds. Warrell, D.A., Cox, T.M. & Firth, J.D.) (Oxford University Press, Oxford, 2003).

  37. 37

    Polihronis, M., Murphy, B.F., Pearse, M.J. & Power, D.A. Heparin-binding epidermal growth factor-like growth factor, an immediate-early gene for mesangial cells, is up-regulated in the Thy-1.1 model. Exp. Nephrol. 4, 271–278 (1996).

  38. 38

    Takemura, T. et al. Heparin-binding EGF-like growth factor is expressed by mesangial cells and is involved in mesangial proliferation in glomerulonephritis. J. Pathol. 189, 431–438 (1999).

  39. 39

    Triantafyllopoulou, A. et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc. Natl. Acad. Sci. USA 107, 3012–3017 (2010).

  40. 40

    Chugh, S. et al. Aminopeptidase A: a nephritogenic target antigen of nephrotoxic serum. Kidney Int. 59, 601–613 (2001).

  41. 41

    Englert, C. et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14, 4662–4675 (1995).

  42. 42

    Elenius, K., Paul, S., Allison, G., Sun, J. & Klagsbrun, M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 16, 1268–1278 (1997).

  43. 43

    Mishra, R., Leahy, P. & Simonson, M.S. Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am. J. Physiol. Renal Physiol. 283, F1151–F1159 (2002).

  44. 44

    Kim, H.S. et al. Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J. Biol. Chem. 282, 16278–16287 (2007).

  45. 45

    Wassef, L., Kelly, D.J. & Gilbert, R.E. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 66, 1805–1814 (2004).

  46. 46

    Advani, A. et al. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology 16, 573–581 (2011).

  47. 47

    Paizis, K. et al. Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. Kidney Int. 55, 2310–2321 (1999).

  48. 48

    Jackson, L.F. et al. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 22, 2704–2716 (2003).

  49. 49

    Luetteke, N.C. et al. TGF α deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73, 263–278 (1993).

  50. 50

    Mann, G.B. et al. Mice with a null mutation of the TGF α gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73, 249–261 (1993).

  51. 51

    Moeller, M.J., Sanden, S.K., Soofi, A., Wiggins, R.C. & Holzman, L.B. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis 35, 39–42 (2003).

  52. 52

    Novak, A., Guo, C., Yang, W., Nagy, A. & Lobe, C.G. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28, 147–155 (2000).

  53. 53

    Shigehara, T. et al. Inducible podocyte-specific gene expression in transgenic mice. J. Am. Soc. Nephrol. 14, 1998–2003 (2003).

  54. 54

    Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).

  55. 55

    Lee, T.C. & Threadgill, D.W. Generation and validation of mice carrying a conditional allele of the epidermal growth factor receptor. Genesis 47, 85–92 (2009).

  56. 56

    Le Jan, S. et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am. J. Pathol. 162, 1521–1528 (2003).

Download references


This work was supported by INSERM, grant ANR-08-EBIO-003 (P.-L.T.) from l'Agence Nationale de la Recherche of France, grant 01GN0805 (K.E.) from the German Federal Ministry of Education and Research (BMBF) and grants CA43793 (S.W.S.) and DK30932 (D.S.) from the US National Institutes of Health. We are grateful to la Fondation pour la Recherche Médicale and la Fondation Lefoulon-Delalande for supporting G.B. and C.F., respectively. We thank L.B. Holzman (Perelman School of Medicine, University of Pennsylvania) for the use of podocin-Cre mice crossed with Z/EGFP mice. We also thank X. Biolchini, C. Kitou, C. Martin, E. Huc and the ERI970 team for assistance in animal care and handling, H. Wegner, R. Maciejewski and T. Felix for technical assistance and J. Peters for help with fluorescence-activated cell sorting (FACS; supported by InnoProfile grant 03IP612 of the BMBF). We acknowledge administrative support from M.-C. Poeuf, V. Oberweiss, A. De Rueda, M. Autran and P. Coudol.

Author information

M.F., G.B. and P.-L.T. conceived the project and experiments. P.-L.T. and N.E. supervised the project. S.S., C.F., M.M., S.V. and E.S. developed methods to culture and analyze primary podocytes and conceived experiments for gene expression analysis. E.R. and M.M. carried out electron microscopy (EM) studies. S.W.S., S.E.Q., J.B.K., D.W.T., I.C. and C.B. helped generate mice with targeted deficiency of HBEGF, TGF-α, epiregulin and Egfr. A.G. and S.G. carried out in situ hybridization studies. D.J.S. and L.M. provided nephrotoxic serum and discussed data with P.-L.T. K.E., C.B. and J.-C.D. also discussed experiments with P.-L.T. and N.E. P.-L.T., G.B., M.M., C.F. and N.S. carried out all in vivo studies. M.F., A.R. and P.C. analyzed human kidney biopsies collected by X.B. G.B. and M.F. contributed equally to the study.

Correspondence to Pierre-Louis Tharaux.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8 and Supplementary Methods (PDF 5129 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bollée, G., Flamant, M., Schordan, S. et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17, 1242–1250 (2011) doi:10.1038/nm.2491

Download citation

Further reading